Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuganlin Oral Liquid is a traditional Chinese medicine (TCM) formulation used primarily for the treatment of repeated infantile respiratory tract infections. It is described as a pure Chinese medicinal recipe and has demonstrated efficacy in modulating immune function, providing symptomatic relief for fever, cough, and asthma, as well as exhibiting antiviral, antibacterial, and anti-inflammatory properties. Clinical studies have shown that it can improve outcomes in children with recurrent respiratory infections compared to standard antipyretic treatments. The formulation is also considered safe based on toxicological testing in animal models; however, further clinical trials are required to confirm its safety and efficacy in humans[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuganlin Oral Liquid.